Inhibition of pancreatic cancer growth by an siRNA targeting SNORA22 and a folic acid-conjugated cationic oligopeptide
Kazuhiro Hiyama, Miki Nishigawa, Kazunori Takagi, Kazuki Sato, Rintaro Iwata Hara, Kaoru Furihata, Kazushige Uchida, Takeshi Wada, Keisuke Taniuchi · 2026
Read Inhibition of pancreatic cancer growth by an siRNA targeting SNORA22 and a folic acid-conjugated cationic oligopeptide by Kazuhiro Hiyama, Miki Nishigawa, Kazunori Takagi, Kazuki Sato, Rintaro Iwata Hara, Kaoru Furihata, Kazushige Uchida, Takeshi Wada, Keisuke Taniuchi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13627270.txt.
Description
Kazuhiro Hiyama and colleagues build a guided missile for gene-silencing therapy in pancreatic cancer, among the deadliest of tumors. Their payload is a small interfering RNA aimed at SNORA22, a tiny RNA that drives the cancer's spread, armored with chemical tweaks that resist blood enzymes. The carrier is a folic acid-tagged peptide that homes to tumor cells. One shape of the tag packed the cargo far better than its mirror form. It entered cells and silenced the target more deeply.
In mice grown from human pancreatic tumor organoids, the complex piled into tumors within a day. It shrank growth more than the standard two-drug chemotherapy. Wide necrosis and little invasion marked the edges. No organ toxicity showed. A delivery problem that has stalled RNA drugs may have a workable answer.
Catalog record
| CREATOR | Kazuhiro Hiyama, Miki Nishigawa, Kazunori Takagi, Kazuki Sato, Rintaro Iwata Hara, Kaoru Furihata, Kazushige Uchida, Takeshi Wada, Keisuke Taniuchi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |